Ovation Fertility has partnered with a new private equity investor: investment funds managed by Morgan Stanley Capital Partners (MSCP), the middle-market-focused private equity team within Morgan Stanley Investment Management. The investment will allow Ovation to continue to grow its service lines and nationwide presence, and to further its mission to reduce the overall cost of having a family through more efficient and effective fertility care.
Ovation® Fertility is pleased to announce that it has partnered with a new private equity investor: investment funds managed by Morgan Stanley Capital Partners (MSCP), the middle-market-focused private equity team within Morgan Stanley Investment Management. The investment supersedes Ovation’s previous private equity partnership with WindRose Health Investors.
The current Ovation leadership team and base of physician shareholders will remain in place, allowing for continued growth under the same innovative business model that has revolutionized the fertility laboratory services business through increased collaboration and widespread implementation of evidence-based best practices. Ovation celebrated its four-year anniversary June 1, 2019, and since its founding, has more than doubled the size of the company across numerous metrics and helped thousands of people become parents through advanced reproductive science.
“I am delighted to announce that after extensive exploration and negotiation, Ovation has accomplished its goal of recapitalization in partnership with one of private equity’s most respected names,” said Nate Snyder, Ovation’s chief executive officer. “Morgan Stanley Capital Partners believes in our business model and appreciates the strong physician relationships we have developed. They are bringing to the executive team new ideas for growth that will propel us to achieve even better patient outcomes. I’m also grateful to our founding financial sponsor, WindRose Health Investors, who took a leap of faith on our vision to reduce the overall cost of having a family through more efficient and effective fertility care.”
“We are excited to invest in Ovation, which is a premier fertility services provider in the United States,” said Steve Rodgers, managing director of Morgan Stanley Capital Partners. “We believe Ovation represents a best-in-class management team who have partnered with industry-leading physician groups and highly attractive laboratories. We look forward to supporting our partner physicians during the coming years of growth, as they deliver the highest quality of care and execute our shared mission to serve individuals and couples across the United States and beyond.”
About Ovation® Fertility
Ovation Fertility is a national network of reproductive endocrinologists and scientific thought leaders focused on reducing the cost of having a family through more efficient and effective fertility care. Ovation’s IVF and genetics laboratories and affiliated practices work collaboratively to raise the bar for IVF treatment, with state-of-the-art, evidence-based fertility services that give hopeful parents the best chance for a successful pregnancy. Physicians partner with Ovation to offer their patients advanced preimplantation genetic testing. Ovation also provides donor eggs that come with a Euploid Embryo Guarantee®, as well as secure frozen egg, embryo and sperm long-term storage; consultative services to help IVF laboratories improve quality and performance; and fertility preservation programs that enable more women to freeze their eggs and build future families. Learn more about Ovation’s vision of a world without infertility at http://www.OvationFertility.com.
About Morgan Stanley Capital Partners
Morgan Stanley Capital Partners, part of Morgan Stanley Investment Management, is a leading middle-market private equity platform that has invested capital in a broad spectrum of industries for over three decades. Morgan Stanley Capital Partners focuses on privately negotiated equity and equity-related investments, primarily in North America, and seeks to create value in portfolio companies primarily in a series of subsectors in the business services, consumer, healthcare and industrials markets, with an emphasis on driving significant organic and acquisition growth through an operationally focused approach. For further information about Morgan Stanley Capital Partners, please visit http://www.morganstanley.com/im/capitalpartners.